NEJM publishes Revolution Medicines Phase 1/2 data on RASONQUE™ in NSCLC
Revolution Medicines said The New England Journal of Medicine has published Phase 1/2 clinical data for RASONQUE (daraxonrasib) in metastatic non-small cell lung cancer.
REDWOOD CITY, Calif., Sept.
02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc.
NASDAQ:RVMD, a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that The New England Journal…